Recombinant Human IL2RA Protein, C-Avi&His tagged, Biotinylated
|Product Overview :||Biotinylated recombinant Human Interleukin-2 Receptor subunit alpha is produced by our Mammalian expression system and the target gene encoding Glu22-Gln240 is expressed with a Avi and 6His tag at the C-terminus.|
- Gene Information
- Related Products
|Description :||Interleukin-2 receptor subunit alpha (IL2RA) is a single-pass type I membrane glycoprotein, contains 2 Sushi (CCP/SCR) domains. IL2RA is expressed on activated T cells and regulatory T cells, and can bind IL2 with low affinity by itself. The interleukin 2 (IL2) receptor alpha (IL2RA) and beta (IL2RB) chains, together with the common gamma chain (IL2RG), constitute the high-affinity IL2 receptor. While homodimeric alpha chains (IL2RA) result in low-affinity receptor, homodimeric beta (IL2RB) chains produce a medium-affinity receptor. CD25 has been previously regarded as an activation marker on dendritic cells. Although both murine and human dendritic cells can express CD25, they do not express the beta-chain of the IL-2 receptor, which is indispensable for the execution of IL-2 signaling.|
|Protein Length :||Glu22-Gln240|
|Storage Buffer :||Supplied as a 0.2 μm filtered solution of PBS, pH7.4|
|Shipping :||Dry ice/ice pack|
|Gene Name :||IL2RA interleukin 2 receptor, alpha [ Homo sapiens (human) ]|
|Official Symbol :||IL2RA|
|Synonyms :||Interleukin-2 receptor subunit alpha; CD25; p55; TAC antigen; IL2-RA; IL-2R subunit alpha; IL-2-RA; IL2RA; IL-2 receptor subunit alpha|
|Gene ID :||3559|
|mRNA Refseq :||NM_000417|
|Protein Refseq :||NP_000408|
|UniProt ID :||P01589|
|◆ Recombinant Protein|
|IL2RA-2068R||Recombinant Rhesus Macaque IL2RA Protein, His (Fc)-Avi-tagged||+Inquiry|
|Il2ra-1677M||Recombinant Mouse Il2ra Protein, His-tagged||+Inquiry|
|IL2RA-319H||Recombinant Human IL2RA Protein, His-tagged||+Inquiry|
|Il2ra-4513M||Recombinant Mouse Il2ra Protein, His (Fc)-Avi-tagged||+Inquiry|
|IL2RA-2698R||Recombinant Rat IL2RA Protein, His (Fc)-Avi-tagged||+Inquiry|
|IL2RA-1015CCL||Recombinant Cynomolgus IL2RA cell lysate||+Inquiry|
|IL2RA-2024MCL||Recombinant Mouse IL2RA cell lysate||+Inquiry|
|IL2RA-2907HCL||Recombinant Human IL2RA cell lysate||+Inquiry|
For Research Use Only. Not intended for any clinical use. No products from Creative BioMart may be resold, modified for resale or used to manufacture commercial products without prior written approval from Creative BioMart.
Q&As (6)Ask a question
The combination of IL2RA and other drugs may produce nausea, vomiting, rash and other adverse reactions, should be monitored.
The frequency of use of IL2RA depends on the specific situation of the patient, and is generally used 1-3 times per week.
IL2RA, in the right dosage and frequency of use, can significantly relieve symptoms of diseases such as autoimmune diseases and organ transplant rejection.
Can assist in the treatment of some types of malignant tumors, but it is not a complete cure for cancer.
The effective rate of IL2RA therapy depends on many factors such as the type of disease, the patient's condition and the treatment regimen, and the effective rate is generally between 50% and 90%.
Indications of IL2RA include a variety of autoimmune diseases, organ transplant rejection and malignant tumors.
Customer Reviews (3)Write a review
Structural stability of IL2RA, that is, whether it can maintain its structural integrity and functional activity under different conditions such as temperature, pH value and storage time, HPLC, CD spectroscopy and other techniques can be used to evaluate the stability. -
Solubility and stability of IL2RA in physiological buffers to ensure its reliability in practical applications. -
To evaluate whether IL2RA has biological activity, we can verify its IL-2 binding ability and signal transduction ability through cell experiments, which are the key functions of IL2RA. -
Ask a Question for All IL2RA Products
Required fields are marked with *
My Review for All IL2RA Products
Required fields are marked with *